Abstract
We performed various analyses on the taxonomic and functional features of the gut microbiome from NSCLC patients treated with immunotherapy to establish a model that may predict whether a patient will benefit from immunotherapy. We collected 65 published whole metagenome shotgun sequencing samples along with 14 samples from our previous study. We systematically studied the taxonomical characteristics of the dataset and used both the random forest (RF) and the multilayer perceptron (MLP) neural network models to predict patients with progression-free survival (PFS) above 6 months versus those below 3 months. Our results showed that the RF classifier achieved the highest F-score (85.2%) and the area under the receiver operating characteristic curve (AUC) (95%) using the protein families (Pfam) profile, and the MLP neural network classifier achieved a 99.9% F-score and 100% AUC using the same Pfam profile. When applying the model trained in the Pfam profile directly to predict the treatment response, we found that both trained RF and MLP classifiers significantly outperformed the stochastic predictor in F-score. Our results suggested that such a predictive model based on functional (e.g., Pfam) rather than taxonomic profile might be clinically useful to predict whether an NSCLC patient will benefit from immunotherapy, as both the F-score and AUC of functional profile outperform that of taxonomic profile. In addition, our model suggested that interactive biological processes such as methanogenesis, one-carbon, and amino acid metabolism might be important in regulating the immunotherapy response that warrants further investigation.
Funder
University of Kansas Start-Up
“Play with a Pro” Lung Cancer Research Fund
Pilot Grant for Cancer Research of the University of Kansas Cancer Center
National Science Foundation CAREER
Reference63 articles.
1. Cancer Statistics, 2021;Siegel;CA Cancer J. Clin.,2021
2. Cancer statistics for the year 2020: An overview;Ferlay;Int. J. Cancer,2021
3. Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Decade of Progress;Shields;Am. Soc. Clin. Oncol. Educ. Book,2021
4. A guide to cancer immunotherapy: From T cell basic science to clinical practice;Waldman;Nat. Rev. Immunol.,2020
5. Pandey, P., Khan, F., Qari, H.A., Upadhyay, T.K., Alkhateeb, A.F., and Oves, M. Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4. Pharmaceuticals, 2022. 15.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献